

Boadie W Dunlop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4623150/publications.pdf>

Version: 2024-02-01

167
papers

7,359
citations

81900

39
h-index

62596

80
g-index

177
all docs

177
docs citations

177
times ranked

9463
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Dopamine in the Pathophysiology of Depression. Archives of General Psychiatry, 2007, 64, 327.	12.3	991
2	Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder. JAMA Psychiatry, 2013, 70, 821.	11.0	455
3	A Randomized, Double-Blind Evaluation of D-Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder in Iraq and Afghanistan War Veterans. American Journal of Psychiatry, 2014, 171, 640-648.	7.2	354
4	MicroRNA 135 Is Essential for Chronic Stress Resiliency, Antidepressant Efficacy, and Intact Serotonergic Activity. Neuron, 2014, 83, 344-360.	8.1	321
5	Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. American Journal of Psychiatry, 2017, 174, 533-545.	7.2	268
6	D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders. JAMA Psychiatry, 2017, 74, 501.	11.0	236
7	Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research, 2019, 111, 59-67.	3.1	197
8	The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. Journal of Psychiatric Research, 2012, 46, 1406-1413.	3.1	185
9	Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy. JAMA Psychiatry, 2015, 72, 1102.	11.0	155
10	Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. Neuron, 2018, 99, 914-924.e3.	8.1	153
11	The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 361-379.	4.8	137
12	Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics, 2019, 20, 37-47.	1.3	126
13	GENDER AS PREDICTOR AND MODERATOR OF OUTCOME IN COGNITIVE BEHAVIOR THERAPY AND PHARMACOTHERAPY FOR ADULT DEPRESSION: AN INDIVIDUAL PATIENT DATA META-ANALYSIS. Depression and Anxiety, 2014, 31, 941-951.	4.1	122
14	Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression. Biological Psychiatry, 2014, 76, 527-535.	1.3	119
15	Predictors of remission in depression to individual and combined treatments (PreDICT): study protocol for a randomized controlled trial. Trials, 2012, 13, 106.	1.6	108
16	Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PreDICT) Study. American Journal of Psychiatry, 2017, 174, 546-556.	7.2	107
17	Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues in Clinical Neuroscience, 2014, 16, 479-490.	3.7	103
18	BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity. Molecular Psychiatry, 2012, 17, 22-35.	7.9	91

#	ARTICLE	IF	CITATIONS
19	Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 222-228.	0.6	82
20	Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics Journal, 2018, 18, 613-622.	2.0	80
21	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biological Psychiatry, 2017, 82, 866-874.	1.3	74
22	Combination Psychotherapy and Antidepressant Medication Treatment for Depression: For Whom, When, and How. Annual Review of Psychology, 2014, 65, 267-300.	17.7	72
23	Symptomatic and Functional Improvement in Employed Depressed Patients. Journal of Clinical Psychopharmacology, 2011, 31, 569-576.	1.4	71
24	The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. World Psychiatry, 2019, 18, 183-191.	10.4	68
25	Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder. Journal of Psychiatric Research, 2012, 46, 375-381.	3.1	67
26	Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology, 2017, 234, 2883-2895.	3.1	65
27	Exploratory structural equation modeling of resting-state fMRI: Applicability of group models to individual subjects. NeuroImage, 2009, 45, 778-787.	4.2	58
28	Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer, 2018, 124, 546-554.	4.1	58
29	Reconciling Variable Findings of White Matter Integrity in Major Depressive Disorder. Neuropsychopharmacology, 2014, 39, 1332-1339.	5.4	57
30	Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational Psychiatry, 2019, 9, 173.	4.8	53
31	Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder. Journal of Clinical Psychiatry, 2013, 74, 1010-1017.	2.2	49
32	Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression. Translational Psychiatry, 2021, 11, 153.	4.8	46
33	Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. Journal of Clinical Psychiatry, 2019, 80, .	2.2	45
34	Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness. Journal of Clinical Psychopharmacology, 2007, 27, 614-619.	1.4	44
35	A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites. Neuropsychopharmacology, 2012, 37, 2830-2836.	5.4	43
36	Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. American Journal of Psychiatry, 2019, 176, 275-286.	7.2	43

#	ARTICLE	IF	CITATIONS
37	Treating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 81-90.	2.2	43
38	Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2017, 7, 40.	2.1	42
39	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	10.3	42
40	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 240.	1.6	41
41	Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression. <i>American Journal of Psychiatry</i> , 2016, 173, 481-490.	7.2	41
42	Correlation between patient and clinician assessments of depression severity in the PREVENT study. <i>Psychiatry Research</i> , 2010, 177, 177-183.	3.3	40
43	Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP). <i>Behavioral Sciences (Basel, Switzerland)</i> , 2014, 4, 511-527.	2.1	40
44	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. <i>Biological Psychiatry</i> , 2007, 62, 1371-1379.	1.3	39
45	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 96-103.	3.1	39
46	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. <i>American Journal of Psychiatry</i> , 2018, 175, 251-261.	7.2	39
47	Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 5645-5658.	1.9	38
48	Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders. <i>Journal of Anxiety Disorders</i> , 2019, 68, 102147.	3.2	38
49	Do alcohol use disorders destabilize the course of bipolar disorder?. <i>Journal of Affective Disorders</i> , 2013, 145, 1-10.	4.1	37
50	Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 237-239.	1.8	37
51	When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates. <i>Journal of Anxiety Disorders</i> , 2019, 61, 89-97.	3.2	37
52	Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 164, 102219.	2.2	37
53	Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature. <i>Scientific Reports</i> , 2021, 11, 21011.	3.3	37
54	DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018, 10, 136.	4.1	36

#	ARTICLE	IF	CITATIONS
55	Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. <i>Journal of Anxiety Disorders</i> , 2019, 68, 102149.	3.2	36
56	Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. <i>Journal of Affective Disorders</i> , 2020, 264, 90-97.	4.1	36
57	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014, 57, 51-57.	3.1	35
58	Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996.. <i>Environmental Health Perspectives</i> , 2002, 110, 1047-1051.	6.0	33
59	Tiagabine for social anxiety disorder. <i>Human Psychopharmacology</i> , 2007, 22, 241-244.	1.5	33
60	Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. <i>Psychoneuroendocrinology</i> , 2016, 69, 161-171.	2.7	33
61	Metabolomic and inflammatory signatures of symptom dimensions in major depression. <i>Brain, Behavior, and Immunity</i> , 2022, 102, 42-52.	4.1	33
62	Acute Swedish Massage Monotherapy Successfully Remediate Symptoms of Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e883-e891.	2.2	31
63	The Impact of HIPAA Authorization on Willingness to Participate in Clinical Research. <i>Annals of Epidemiology</i> , 2007, 17, 899-905.	1.9	29
64	Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. <i>International Clinical Psychopharmacology</i> , 2009, 24, 204-213.	1.7	29
65	Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder. <i>PLoS ONE</i> , 2013, 8, e78292.	2.5	29
66	Mediators of Sexual Functioning and Marital Quality in Chronically Depressed Adults with and Without a History of Childhood Sexual Abuse. <i>Journal of Sexual Medicine</i> , 2015, 12, 813-823.	0.6	29
67	Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. <i>Journal of Affective Disorders</i> , 2018, 238, 1-7.	4.1	28
68	Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity. <i>PLoS Biology</i> , 2017, 15, e2002690.	5.6	28
69	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. <i>Translational Psychiatry</i> , 2021, 11, 88.	4.8	27
70	ENHANCING HISPANIC PARTICIPATION IN MENTAL HEALTH CLINICAL RESEARCH: DEVELOPMENT OF A SPANISH-SPEAKING DEPRESSION RESEARCH SITE. <i>Depression and Anxiety</i> , 2014, 31, 258-267.	4.1	26
71	Prediction of treatment outcomes in major depressive disorder. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 669-672.	3.1	26
72	Moving pharmacoepigenetics tools for depression toward clinical use. <i>Journal of Affective Disorders</i> , 2019, 249, 336-346.	4.1	25

#	ARTICLE	IF	CITATIONS
73	Preconsent education about research processes improved African Americans' willingness to participate in clinical research. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 872-877.	5.0	24
74	Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. <i>International Clinical Psychopharmacology</i> , 2007, 22, 1-11.	1.7	24
75	Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. <i>Depression and Anxiety</i> , 2017, 34, 246-256.	4.1	23
76	Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. <i>Depression and Anxiety</i> , 2018, 35, 992-1000.	4.1	23
77	Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2018, 8, 37.	2.1	23
78	Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression. <i>Journal of Affective Disorders</i> , 2020, 266, 22-29.	4.1	22
79	An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change. <i>Psychological Services</i> , 2021, 18, 606-618.	1.5	22
80	Somatic symptoms in treatment-naïve Hispanic and non-Hispanic patients with major depression. <i>Depression and Anxiety</i> , 2020, 37, 156-165.	4.1	21
81	Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry. <i>BMC Medicine</i> , 2020, 18, 170.	5.5	21
82	The effects of sertraline on psychopathic traits. <i>International Clinical Psychopharmacology</i> , 2011, 26, 329-337.	1.7	20
83	Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 156-173.	0.8	20
84	Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. <i>Psychophysiology</i> , 2020, 57, e13356.	2.4	19
85	A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. <i>Journal of Psychopharmacology</i> , 2022, 36, 368-377.	4.0	19
86	Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial. <i>BMC Psychiatry</i> , 2019, 19, 420.	2.6	18
87	Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder. <i>Psychiatry Research</i> , 2020, 290, 113017.	3.3	18
88	A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders. <i>Journal of Medical Ethics</i> , 2009, 35, 384-389.	1.8	17
89	Conceptualizing Treatment Nonadherence in Patients with Bipolar Disorder and PTSD. <i>CNS Spectrums</i> , 2011, 16, 11-20.	1.2	17
90	ERICH3: vesicular association and antidepressant treatment response. <i>Molecular Psychiatry</i> , 2021, 26, 2415-2428.	7.9	17

#	ARTICLE	IF	CITATIONS
91	REVIEW OF NUTRITIONAL SUPPLEMENTS FOR THE TREATMENT OF BIPOLAR DEPRESSION. <i>Depression and Anxiety</i> , 2014, 31, 379-390.	4.1	16
92	Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75â€“225â€“mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study. <i>International Clinical Psychopharmacology</i> , 2008, 23, 357-363.	1.7	15
93	Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment. <i>Frontiers in Neuroscience</i> , 2019, 13, 926.	2.8	15
94	Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence.. <i>Journal of Consulting and Clinical Psychology</i> , 2018, 86, 189-199.	2.0	15
95	Recovery and subsequent recurrence in patients with recurrent major depressive disorder. <i>Journal of Psychiatric Research</i> , 2012, 46, 708-715.	3.1	14
96	Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment. <i>Psychiatry Research</i> , 2017, 257, 386-392.	3.3	14
97	Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. <i>Journal of Psychiatric Research</i> , 2019, 116, 178-184.	3.1	14
98	Will current socioeconomic trends produce a depressing future for men?. <i>British Journal of Psychiatry</i> , 2011, 198, 167-168.	2.8	13
99	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 200-206.	1.4	13
100	Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. <i>Psychological Medicine</i> , 2019, 49, 1869-1878.	4.5	13
101	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 933-945.	1.2	13
102	Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges. <i>Biological Psychiatry</i> , 2021, 90, 236-242.	1.3	13
103	US Psychiatric Residentsâ€™ Treatment of Patients With Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 231-236.	1.4	12
104	Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2018, 8, 64.	2.1	12
105	How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine. <i>Human Psychopharmacology</i> , 2014, 29, 528-536.	1.5	11
106	A Virtual Standardized Patientâ€“Based Assessment Tool to Evaluate Psychiatric Residentsâ€™ Psychopharmacology Proficiency. <i>Academic Psychiatry</i> , 2020, 44, 693-700.	0.9	11
107	Assessing Residentsâ€™ Confidence in the Context of Pharmacotherapy Competence. <i>Academic Psychiatry</i> , 2017, 41, 350-353.	0.9	10
108	Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression. <i>Journal of Affective Disorders</i> , 2022, 307, 254-263.	4.1	10

#	ARTICLE	IF	CITATIONS
109	Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 454-459.	1.4	9
110	Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. <i>Journal of Affective Disorders</i> , 2018, 229, 111-119.	4.1	9
111	Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms. <i>Journal of Psychiatric Research</i> , 2020, 120, 154-162.	3.1	9
112	Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings. <i>Complementary Therapies in Medicine</i> , 2021, 56, 102593.	2.7	9
113	Dry Those Crying Eyes. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 295-303.	1.4	9
114	Public Health Consequences of State Immigration Laws. <i>Southern Medical Journal</i> , 2011, 104, 718-719.	0.7	9
115	The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 84-92.	4.1	9
116	Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 718539.	2.6	9
117	Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. <i>Psychiatry Research</i> , 2021, 296, 113649.	3.3	8
118	Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics. <i>Psychopharmacology Bulletin</i> , 2003, 37, 99-117.	0.0	8
119	Use of Dialectical Behavior Therapy in Borderline Personality Disorder: A View From Residency. <i>Academic Psychiatry</i> , 2007, 31, 218-224.	0.9	7
120	Cognitive Effects of Quetiapine XR in Patients With Euthymic Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 383-385.	1.4	7
121	Survey of Investigators' Opinions on the Acceptability of Interactions With Patients Participating in Clinical Trials. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 323-327.	1.4	6
122	Should Sensitive Information From Clinical Trials Be Included in Electronic Medical Records?. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 685.	7.4	5
123	Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 24-28.	3.1	5
124	Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 172-179.	1.4	5
125	Enhancing Informed Consent in Clinical Trials and Exploring Resistances to Disclosing Adverse Clinical Trial Results. <i>American Journal of Bioethics</i> , 2009, 9, 39-41.	0.9	4
126	Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder. <i>Current Psychiatry Reviews</i> , 2010, 6, 28-45.	0.9	4

#	ARTICLE	IF	CITATIONS
127	Depression Worsening Associated With Lorcaserin. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 747-749.	1.4	4
128	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 539-547.	0.5	4
129	Moving on With Monoamine Oxidase Inhibitors. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 50-52.	0.8	4
130	When Should a Patient Be Declared Recovered From a Major Depressive Episode?. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1026-e1028.	2.2	4
131	Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. <i>Psychopharmacology Bulletin</i> , 2009, 42, 5-20.	0.0	4
132	Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder. <i>Psychiatry Research</i> , 2022, 308, 114354.	3.3	4
133	The structure of personality disorders within a depressed sample: Implications for personalizing treatment. <i>Personalized Medicine in Psychiatry</i> , 2017, 1-2, 59-64.	0.1	3
134	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al.. <i>American Journal of Psychiatry</i> , 2018, 175, 576-577.	7.2	3
135	Model structure for protocol adherence utilizing a manualized therapeutic massage intervention. <i>Journal of Complementary and Integrative Medicine</i> , 2019, 16, .	0.9	3
136	Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, Publish Ahead of Print, 501-503.	1.4	3
137	Antidepressant Signal Detection in the Clinical Trials Vortex. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e657-e659.	2.2	3
138	Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).. <i>Innovations in Clinical Neuroscience</i> , 2022, 19, 26-32.	0.1	3
139	Two years of maintenance treatment with venlafaxine xr 75-225 mg/d: Efficacy in patients with recurrent unipolar major depression. <i>European Psychiatry</i> , 2007, 22, S239-S240.	0.2	2
140	The Over-Under on the Misdiagnosis of Bipolar Disorder: A Systematic Review. <i>Current Psychiatry Reviews</i> , 2015, 11, 222-234.	0.9	2
141	Ten ways to improve the treatment of depression and anxiety in adults. <i>Mental Health in Family Medicine</i> , 2013, 10, 175-81.	0.2	2
142	Exercise for depression: efficacy, safety and clinical trial implications. <i>Psychopharmacology Bulletin</i> , 2008, 41, 65-75.	0.0	2
143	An Additional Consideration for Comparisons of Antidepressants Versus Placebo. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 641-642.	1.4	1
144	A Simple Question Answered: Adding Moderate-Dosage Lithium Does Not Help Patients With Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2013, 170, 9-11.	7.2	1

#	ARTICLE	IF	CITATIONS
145	549. DNA Methylation Biomarkers and Treatment Effects of a Corticotropin Releasing Hormone Type 1 Receptor Antagonist in a Biologically-Defined Subset of PTSD-Patients. <i>Biological Psychiatry</i> , 2017, 81, S222.	1.3	1
146	688. The CRH-1 Receptor Antagonist Saga in Mood and Anxiety Disorders: The Good, the Bad and the Ugly. <i>Biological Psychiatry</i> , 2017, 81, S279.	1.3	1
147	How Shall I Diagnose Thee? Let Me Count the Ways. <i>Biological Psychiatry</i> , 2017, 82, 306-308.	1.3	1
148	Surveying Psychiatrists' Psychopharmacology Practices Across Common Clinical Scenarios. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 445-449.	0.8	1
149	Test-Retest Reliability of the SERT Imaging Agent [¹¹ C]-HOMADAM in Healthy Humans. <i>Journal of Nuclear Medicine</i> , 2018, 59, 315-319.	5.0	1
150	Response to: Goldberg et al. and Severance et al. Letters to the Editor: The clinical significance of improving remission over standard of care – The reality of treatment resistant-based therapies. <i>Journal of Psychiatric Research</i> , 2019, 114, 211-213.	3.1	1
151	49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial. <i>CNS Spectrums</i> , 2019, 24, 202-203.	1.2	1
152	Navigating the Novel Psychotropics. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 1-2.	0.8	1
153	Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 111-112.	1.7	1
154	Commentary. Primary Care Companion To the Journal of Clinical Psychiatry, 2005, 7, 300-3.	0.6	1
155	Pharmacogenetic Decision Support Tools: A Component of Precision Medicine for Psychiatry?. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 3s-4s.	0.8	1
156	Neuroimaging Advances for Depression. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2017, 2017, .	0.1	1
157	Psychosocial context of antidepressant response. <i>Biological Psychiatry</i> , 2005, 57, 314.	1.3	0
158	Test-Retest reliability of the SERT imaging agent [¹¹ C]HOMADAM in healthy humans. <i>NeuroImage</i> , 2010, 52, S110.	4.2	0
159	Pharmacology and neuroimaging of antidepressant action. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012, 106, 643-655.	1.8	0
160	Ziprasidone monotherapy is ineffective for bipolar-associated anxiety. <i>Evidence-Based Mental Health</i> , 2014, 17, 109-109.	4.5	0
161	525. The Temporal Stability of Cognitive Functioning and Functional Capacity in Women with PTSD. <i>Biological Psychiatry</i> , 2017, 81, S213.	1.3	0
162	597. Clinical Staging of Major Depression: Multimodal-Imaging Approach. <i>Biological Psychiatry</i> , 2017, 81, S241-S242.	1.3	0

#	ARTICLE	IF	CITATIONS
163	Imaging the Future of Major Depression. Focus (American Psychiatric Publishing), 2018, 16, 3s-3s.	0.8	0
164	150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression. CNS Spectrums, 2020, 25, 295-296.	1.2	0
165	Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Focus (American Psychiatric Publishing), 2021, 19, 76-85.	0.8	0
166	Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial. CNS Spectrums, 2021, 26, 169-170.	1.2	0
167	Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study. Psychopharmacology Bulletin, 2021, 51, 8-30.	0.0	0